欧洲嗜酸性肉芽肿性多血管炎多国专家调研:当前诊疗实践
OBJECTIVES: Real-world practice patterns of eosinophilic granulomatosis with polyangiitis (EGPA) remain poorly defined. This study aimed to describe current diagnostic and therapeutic approaches across experienced European centres, identifying areas of convergence and variability…
要点
- 多数专家在诊断时即启动抗IL-5治疗,但诱导方案选择差异显著。
- 组织学确诊报告率不足25%,多学科诊疗和心肾筛查广泛采用。
- 患者报告结局工具使用不一致,尽管普遍认可其价值。
核心结论
- 欧洲EGPA诊疗实践存在显著异质性,反映缺乏验证标准、标准化活动指标和治疗算法。
- 需协调前瞻性研究和统一循证指南以优化患者结局。
研究设计与样本
- 44项在线问卷,由专家小组审核并在欧洲EGPA研究组内发放,2025年4月至8月匿名收集回复进行统计分析。
主要发现
- 多学科诊疗及心脏和肾脏受累筛查被广泛采用。
- 组织学确诊报告率不足25%。
- 超过半数受访者在诊断时启动抗IL-5治疗。
- 重症患者首选诱导方案为糖皮质激素联合利妥昔单抗和美泊利珠单抗。
- 糖皮质激素减量方案各异,多数临床医生目标在12个月内停药。
关键数值与推荐
- 组织学确诊报告率不足25%。
- 超过半数受访者在诊断时启动抗IL-5治疗。
- 重症患者首选诱导方案为糖皮质激素、利妥昔单抗和美泊利珠单抗联合。
- 多数临床医生目标在12个月内停用糖皮质激素。
临床怎么用
- 应重视多学科诊疗及心脏、肾脏受累筛查。
- 需关注抗IL-5治疗启动时机和重症诱导方案的个体化选择。
- 应规范使用患者报告结局指标和疾病特异性问卷。
- 可借助倡导团体加强患者教育和转诊。
局限性
- 基于专家问卷的横断面调查,可能存在回忆偏倚和选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Real-world practice patterns of eosinophilic granulomatosis with polyangiitis (EGPA) remain poorly defined. This study aimed to describe current diagnostic and therapeutic approaches across experienced European centres, identifying areas of convergence and variability to inform future standardization of care. METHODS: We distributed a 44-item online survey covering diagnostic evaluation, treatment strategies, patient-reported outcome measures (PROMs) and the role of patient advocacy groups. The survey was reviewed by an expert panel and disseminated within the European EGPA Study Group. Responses were collected anonymously between April and August 2025 for statistical analysis. RESULTS: Fifty-four experts from six countries participated, most with long-standing experience and substantial EGPA caseloads. Multidisciplinary care and screening for cardiac and renal involvement were widely adopted; histological confirmation was reported in fewer than 25% of cases. Treatment strategies varied considerably: over half of respondents initiated anti-IL-5 therapy at diagnosis, and the combination of glucocorticoids, rituximab and mepolizumab was the preferred induction regimen in severe disease. CS tapering protocols differed, with most clinicians targeting withdrawal within 12 months. PROMs and disease-specific questionnaires were used inconsistently, despite broad recognition of their value. Advocacy groups were viewed as crucial, particularly for patient education and referral. CONCLUSION: This first multinational survey reveals substantial heterogeneity in real-world diagnostic and therapeutic practice, reflecting gaps in validated criteria, standardized activity measures and treatment algorithms. These findings highlight the need for coordinated prospective research and harmonized evidence-based guidance to optimize outcomes for patients with EGPA.
引用
- Conticini E, Emmi G, Grazzini S, et al. Current management of eosinophilic granulomatosis with polyangiitis across Europe: insights from a multinational expert survey. Rheumatology (Oxford). 2026. PMID: 42015376. doi:10.1093/rheumatology/keag218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。